4D pharma has provided an extensive clinical programme update on MRx0518, its lead oncology candidate which is being evaluated in three ongoing clinical trials. Focus is on Part B of the Phase I/II combination study with MSD’s Keytruda, where enrolment is progressing well and is expected to complete in Q4 2021. It is too early for conclusions to be drawn, but ‘first signals of anti-tumour activity’ has been observed in bladder cancer. Clinical outcome data is expected from the open-label study l ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oncology programme update
- Published:
03 Feb 2021 -
Author:
Edward Thomason -
Pages:
3
4D pharma has provided an extensive clinical programme update on MRx0518, its lead oncology candidate which is being evaluated in three ongoing clinical trials. Focus is on Part B of the Phase I/II combination study with MSD’s Keytruda, where enrolment is progressing well and is expected to complete in Q4 2021. It is too early for conclusions to be drawn, but ‘first signals of anti-tumour activity’ has been observed in bladder cancer. Clinical outcome data is expected from the open-label study l ....